Mobocertinib 40 mg (Moboxen)

Description

Mobocertinib 40 mg is a prescription medication used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It is a first-in-class drug, which means it is the first to be approved for this indication.

How does it work?
Mobocertinib works by blocking the activity of the epidermal growth factor receptor (EGFR), a protein that helps cancer cells grow and spread. EGFR exon 20 insertion mutations are a type of genetic mutation that occurs in the EGFR gene. These mutations make the EGFR protein more active, which can lead to the growth of cancer cells.

What is the dosage?
The recommended dose of mobocertinib is 40 mg once daily. It is taken as an oral capsule.

What are the side effects?
The most common side effects of mobocertinib are diarrhea, rash, nausea, stomatitis (inflammation of the mouth), vomiting, decreased appetite, paronychia (inflammation of the nail folds), fatigue, dry skin, and musculoskeletal pain.

Serious side effects that can occur with mobocertinib include QTc prolongation (a heart rhythm disorder), interstitial lung disease/pneumonitis (inflammation of the lungs), and cardiac toxicity (heart problems).

Is it safe to take mobocertinib?
Mobocertinib can cause serious side effects, so it is essential to talk to your doctor about the risks and benefits of this medication before taking it. Mobocertinib should not be used by women who are pregnant or breastfeeding. It should also be avoided by people with certain heart conditions or liver problems.